Cargando…

In vitro synergistic activity of antibiotic combinations against Brucella melitensis using E-test methodology

The treatment of brucellosis is still problematic, because of high rates of treatment failure or relapses. As the microorganism is an intracellular pathogen, treatment requires combined regimens. However, limited existing data on in vitro combinations are avaliable for Brucellae. The aim of this stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Kilic, Selcuk, Dizbay, Murat, Hizel, Kenan, Arman, Dilek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Microbiologia 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3768412/
https://www.ncbi.nlm.nih.gov/pubmed/24031207
http://dx.doi.org/10.1590/S1517-83822008000200006
_version_ 1782283777372848128
author Kilic, Selcuk
Dizbay, Murat
Hizel, Kenan
Arman, Dilek
author_facet Kilic, Selcuk
Dizbay, Murat
Hizel, Kenan
Arman, Dilek
author_sort Kilic, Selcuk
collection PubMed
description The treatment of brucellosis is still problematic, because of high rates of treatment failure or relapses. As the microorganism is an intracellular pathogen, treatment requires combined regimens. However, limited existing data on in vitro combinations are avaliable for Brucellae. The aim of this study was to investigate the in vitro efficacy of various traditional and new antibiotic combinations against 16 Brucella melitensis strains. The combination effect of antimicrobial agents was evaluated by E-test synergy method to obtain a fractional inhibitory concentration (FIC) index. Co-Trimoxazole (SXT) and moxifloxocin (MXF) exhibited the lowest MIC, while Rifampin (RIF) had the highest MIC in the study. Combinations with RIF showed the best synergistic activity (100% of RIF-tetracycline (TET), and 87.5% of RIF-SXT). Synergistic activity was also detected at seven (43.7%) of ciprofloxocin (CIP)-SXT, four (25%) of TET-MXF, and two (12.5%) of TET-SXT combinations. The combinations that demonstrated additivity were TET-SXT, CIP-SXT and TET-MXF. Antagonism was observed only with the TET-Streptomycin (STR) combination in three strains (18.8%). Further work including randomized controlled clinical trials is required to fully evaluate the usefulness of these data.
format Online
Article
Text
id pubmed-3768412
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher Sociedade Brasileira de Microbiologia
record_format MEDLINE/PubMed
spelling pubmed-37684122013-09-12 In vitro synergistic activity of antibiotic combinations against Brucella melitensis using E-test methodology Kilic, Selcuk Dizbay, Murat Hizel, Kenan Arman, Dilek Braz J Microbiol Medical Microbiology The treatment of brucellosis is still problematic, because of high rates of treatment failure or relapses. As the microorganism is an intracellular pathogen, treatment requires combined regimens. However, limited existing data on in vitro combinations are avaliable for Brucellae. The aim of this study was to investigate the in vitro efficacy of various traditional and new antibiotic combinations against 16 Brucella melitensis strains. The combination effect of antimicrobial agents was evaluated by E-test synergy method to obtain a fractional inhibitory concentration (FIC) index. Co-Trimoxazole (SXT) and moxifloxocin (MXF) exhibited the lowest MIC, while Rifampin (RIF) had the highest MIC in the study. Combinations with RIF showed the best synergistic activity (100% of RIF-tetracycline (TET), and 87.5% of RIF-SXT). Synergistic activity was also detected at seven (43.7%) of ciprofloxocin (CIP)-SXT, four (25%) of TET-MXF, and two (12.5%) of TET-SXT combinations. The combinations that demonstrated additivity were TET-SXT, CIP-SXT and TET-MXF. Antagonism was observed only with the TET-Streptomycin (STR) combination in three strains (18.8%). Further work including randomized controlled clinical trials is required to fully evaluate the usefulness of these data. Sociedade Brasileira de Microbiologia 2008 2008-06-01 /pmc/articles/PMC3768412/ /pubmed/24031207 http://dx.doi.org/10.1590/S1517-83822008000200006 Text en © Sociedade Brasileira de Microbiologia http://creativecommons.org/licenses/by-nc/3.0/ All the content of the journal, except where otherwise noted, is licensed under a Creative Commons License
spellingShingle Medical Microbiology
Kilic, Selcuk
Dizbay, Murat
Hizel, Kenan
Arman, Dilek
In vitro synergistic activity of antibiotic combinations against Brucella melitensis using E-test methodology
title In vitro synergistic activity of antibiotic combinations against Brucella melitensis using E-test methodology
title_full In vitro synergistic activity of antibiotic combinations against Brucella melitensis using E-test methodology
title_fullStr In vitro synergistic activity of antibiotic combinations against Brucella melitensis using E-test methodology
title_full_unstemmed In vitro synergistic activity of antibiotic combinations against Brucella melitensis using E-test methodology
title_short In vitro synergistic activity of antibiotic combinations against Brucella melitensis using E-test methodology
title_sort in vitro synergistic activity of antibiotic combinations against brucella melitensis using e-test methodology
topic Medical Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3768412/
https://www.ncbi.nlm.nih.gov/pubmed/24031207
http://dx.doi.org/10.1590/S1517-83822008000200006
work_keys_str_mv AT kilicselcuk invitrosynergisticactivityofantibioticcombinationsagainstbrucellamelitensisusingetestmethodology
AT dizbaymurat invitrosynergisticactivityofantibioticcombinationsagainstbrucellamelitensisusingetestmethodology
AT hizelkenan invitrosynergisticactivityofantibioticcombinationsagainstbrucellamelitensisusingetestmethodology
AT armandilek invitrosynergisticactivityofantibioticcombinationsagainstbrucellamelitensisusingetestmethodology